Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ARL6IP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ARL6IP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ARL6IP1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ARL6IP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ARL6IP1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ARL6IP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ARL6IP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ARL6IP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ARL6IP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ARL6IP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00431544 | Stomach | SIM | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 11/708 | 78/18723 | 1.62e-04 | 3.55e-03 | 11 |
GO:009015011 | Stomach | SIM | establishment of protein localization to membrane | 20/708 | 260/18723 | 2.18e-03 | 2.27e-02 | 20 |
GO:005254729 | Thyroid | HT | regulation of peptidase activity | 71/1272 | 461/18723 | 6.39e-11 | 9.11e-09 | 71 |
GO:005254829 | Thyroid | HT | regulation of endopeptidase activity | 64/1272 | 432/18723 | 2.80e-09 | 2.68e-07 | 64 |
GO:004586129 | Thyroid | HT | negative regulation of proteolysis | 54/1272 | 351/18723 | 1.31e-08 | 1.08e-06 | 54 |
GO:005134628 | Thyroid | HT | negative regulation of hydrolase activity | 54/1272 | 379/18723 | 1.80e-07 | 9.53e-06 | 54 |
GO:001095126 | Thyroid | HT | negative regulation of endopeptidase activity | 40/1272 | 252/18723 | 4.32e-07 | 1.92e-05 | 40 |
GO:001046627 | Thyroid | HT | negative regulation of peptidase activity | 41/1272 | 262/18723 | 4.59e-07 | 2.02e-05 | 41 |
GO:000660528 | Thyroid | HT | protein targeting | 46/1272 | 314/18723 | 6.55e-07 | 2.70e-05 | 46 |
GO:200011629 | Thyroid | HT | regulation of cysteine-type endopeptidase activity | 36/1272 | 235/18723 | 3.74e-06 | 1.23e-04 | 36 |
GO:004328129 | Thyroid | HT | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 32/1272 | 209/18723 | 1.29e-05 | 3.31e-04 | 32 |
GO:200011725 | Thyroid | HT | negative regulation of cysteine-type endopeptidase activity | 17/1272 | 86/18723 | 5.68e-05 | 1.09e-03 | 17 |
GO:004315424 | Thyroid | HT | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 16/1272 | 78/18723 | 5.83e-05 | 1.11e-03 | 16 |
GO:009015025 | Thyroid | HT | establishment of protein localization to membrane | 34/1272 | 260/18723 | 1.83e-04 | 2.69e-03 | 34 |
GO:00066137 | Thyroid | HT | cotranslational protein targeting to membrane | 8/1272 | 31/18723 | 8.56e-04 | 9.17e-03 | 8 |
GO:00717867 | Thyroid | HT | endoplasmic reticulum tubular network organization | 6/1272 | 18/18723 | 8.86e-04 | 9.30e-03 | 6 |
GO:00070297 | Thyroid | HT | endoplasmic reticulum organization | 13/1272 | 87/18723 | 5.73e-03 | 3.72e-02 | 13 |
GO:0006605113 | Thyroid | PTC | protein targeting | 180/5968 | 314/18723 | 6.81e-21 | 1.19e-18 | 180 |
GO:0090150112 | Thyroid | PTC | establishment of protein localization to membrane | 149/5968 | 260/18723 | 1.64e-17 | 1.59e-15 | 149 |
GO:000702915 | Thyroid | PTC | endoplasmic reticulum organization | 51/5968 | 87/18723 | 2.37e-07 | 4.15e-06 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARL6IP1 | SNV | Missense_Mutation | novel | c.568G>A | p.Glu190Lys | p.E190K | Q15041 | protein_coding | tolerated(0.26) | benign(0.212) | TCGA-B6-A402-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PD |
ARL6IP1 | SNV | Missense_Mutation | | c.37N>C | p.Ala13Pro | p.A13P | Q15041 | protein_coding | tolerated(0.07) | possibly_damaging(0.806) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ARL6IP1 | insertion | In_Frame_Ins | novel | c.94_95insATACAGAAAAGGAAACTGGCAGATTTTCATTCACATTCATTT | p.Met32delinsAsnThrGluLysGluThrGlyArgPheSerPheThrPheIleLeu | p.M32delinsNTEKETGRFSFTFIL | Q15041 | protein_coding | | | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ARL6IP1 | SNV | Missense_Mutation | | c.374G>A | p.Arg125His | p.R125H | Q15041 | protein_coding | deleterious(0.04) | probably_damaging(0.959) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ARL6IP1 | SNV | Missense_Mutation | | c.142N>T | p.Ile48Phe | p.I48F | Q15041 | protein_coding | tolerated(0.11) | benign(0.255) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
ARL6IP1 | SNV | Missense_Mutation | novel | c.517G>C | p.Gly173Arg | p.G173R | Q15041 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AG-A00Y-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ARL6IP1 | SNV | Missense_Mutation | | c.600N>T | p.Lys200Asn | p.K200N | Q15041 | protein_coding | deleterious(0.02) | possibly_damaging(0.829) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
ARL6IP1 | SNV | Missense_Mutation | novel | c.22N>G | p.Ser8Gly | p.S8G | Q15041 | protein_coding | tolerated(0.22) | benign(0.049) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARL6IP1 | SNV | Missense_Mutation | rs748922543 | c.427N>A | p.Val143Ile | p.V143I | Q15041 | protein_coding | tolerated(1) | benign(0.005) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ARL6IP1 | SNV | Missense_Mutation | | c.390N>T | p.Lys130Asn | p.K130N | Q15041 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |